Amryt announced that the Dutch Ministry of Health has approved Myalepta(R) (metreleptin) for reimbursement in the Netherlands as an adjunct to diet as replacement therapy for the treatment of leptin deficiency in patients with congenital or acquired general lipodystrophy (GL) in adults and children two years of age and above. Myalepta(R) received marketing authorisation from the European Medicines Agency in 2018.